|
Product Description
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise.
Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits.
Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.
Features
- Used Book in Good Condition
Customers Who Bought This Item Also Bought
- The Pharmagellan Guide to Biotech Forecasting and Valuation
- New Drugs: An Insider's Guide to the FDA's New Drug Approval Process for Scientists, Investors and Patients
- The BioTech Primer
- The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines
- Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves
- Managing Biotechnology: From Science to Market in the Digital Age
- Her-2: The Making of Herceptin, a Revolutionary Treatment for Breast Cancer
- Science Lessons: What the Business of Biotech Taught Me About Management
- The Billion Dollar Molecule: One Company's Quest for the Perfect Drug
- The Antidote: Inside the World of New Pharma
*If this is not the "Genentech: The Beginnings of Biotech (Synthesis)" product you were looking for, you can check the other results by clicking this link. Details were last updated on Nov 14, 2024 15:45 +08.